Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma Our study included a broad cohort of ...
Patients with a lung neoplasm, NSCLC histology, and treatment information in their notes were selected from a repository of over 27 million patients. From these, 200 were randomly selected for this ...
Interest in cell therapy has increased in recent years, with additional focus on leveraging this as a strategy to fight tumors by harnessing the immune system. Cell therapy technologies include ...
For those considering adding Organ-on-a-chip (OOC) technology into the workflow, it may be unclear where to start. Firstly, using a commercially available solution, such as CN Bio's PhysioMimix ®, ...
Programmed cell death (PCD) stands at the forefront of innovation in experimental pharmacology and drug discovery, providing fundamental insights into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results